New Drug for Treatment of Malaria, with Low Risk of Cross Resistance

Dzikowski Ron, HUJI, School of Medicine - IMRIC, Microbiology and Molecular Genetics
Nasereddin Abed, HUJI, School of Medicine - IMRIC

Current Development stage

TRL4 - POC & Safety of candidate drug formulation is demonstrated in defined animal model



The invention relates to an agent against the tropical disease malaria. With an estimated 200 million infected patients worldwide and half a million fatal outcomes, malaria is one of the most dangerous infective diseases worldwide.


Our Innovation

  • Inhibition of the growth of erythrocytic stages of Plasmodium para-sites
  • No structural relation to established antimalarial drugs
  • Low risk of cross-resistance with established antimalarial drugs


The invented compound class against malaria inhibits the growth erythrocytic (human red blood cell) stages of plasmodium para- sites. Since the compounds are structurally unrelated to existing anti-malaria drugs, the risk of cross-resistance is low


Fig. 1:N-Unsubstituted 3,4-bis(indol-3-yl)cyclobut-3- ene-1,2-diones“

In fig. 1 the claimed Markush structure „N- Unsubstituted 3,4-bis(indol-3-yl) cyclobut-3- ene-1,2-diones as antimalarial drugs“ is de- picted, in which A(n), X, E, L, R, Y, and M(p) embody defined atoms or atom groups.

Expected Impact

Malaria is caused by unicellular Plasmodium parasites which are transmitted by the bite of mosquitoes. Although several medicines are available for prophylaxis and treatment of acute infection, their application is severely hampered by emerging resistances of the parasites. Novel drugs displaying a low risk of cross-resistance with established medicines are urgently needed.

Patent Status

Granted US 10,287,271

Contact for more information:

Shani Bullock
VP, Business Development, Healthcare